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Unravelling the genetic basis of 
simplex Retinitis Pigmentosa cases
Nereida Bravo-Gil1,2,*, María González-del Pozo1,2,*, Marta Martín-Sánchez1, Cristina Méndez-
Vidal1,2, Enrique Rodríguez-de la Rúa3,4, Salud Borrego1,2 & Guillermo Antiñolo1,2
Retinitis Pigmentosa (RP) is the most common form of inherited retinal dystrophy (IRD) characterized 
ultimately by photoreceptors degeneration. Exhibiting great clinical and genetic heterogeneity, RP 
can be inherited as an autosomal dominant (ad), autosomal recessive (ar) and X-linked (xl) disorder. 
Although the relative prevalence of each form varies somewhat between populations, a major 
proportion (41% in Spain) of patients represent simplex cases (sRP) in which the mode of inheritance 
is unknown. Molecular genetic diagnostic is crucial, but also challenging, for sRP patients because 
any of the 81 RP genes identified to date may be causative. Herein, we report the use of a customized 
targeted gene panel consisting of 68 IRD genes for the molecular characterization of 106 sRP cases. 
The diagnostic rate was 62.26% (66 of 106) with a proportion of clinical refinements of 30.3%, 
demonstrating the high efficiency of this genomic approach even for clinically ambiguous cases. The 
high number of patients diagnosed here has allowed us to study in detail the genetic basis of the sRP. 
The solved sRP cohort is composed of 62.1% of arRP cases, 24.2% of adRP and 13.6% of xlRP, which 
implies consequences for counselling of patients and families.
Retinitis Pigmentosa (RP [MIM 268000]) is the most prevalent form of inherited retinal dystrophy (IRD) affect-
ing 1:3,000 to 4,000 individuals worldwide1. Typical RP is characterized by early loss of rod photoreceptors, man-
ifesting with initial night blindness and tunnel vision, followed by the secondary loss of cone photoreceptors 
leading to decreased visual acuity and macular affectation2. However, the age of onset, disease progression and 
severity of symptoms can vary markedly among patients, even within the same family1. RP is a genetic disorder 
inherited as Mendelian traits in most cases. The frequencies of autosomal dominant (adRP), autosomal recessive 
(arRP) and X-linked RP (xlRP) are reported to be 12%, 39% and 4%, respectively, in Spain3. Although the relative 
prevalence of each form varies somewhat between populations, a major proportion (40% or higher) of patients 
represent isolated or simplex cases (sRP)4. Other types of non-Mendelian inheritance as mitochondrial inher-
itance5, digenism6 and uniparental isodisomy7 have also been described in RP. RP is also a highly heterogeneous 
genetic disorder, with mutations in more than 80 genes and loci identified to date (http://www.sph.uth.tm.edu/
Retnet/ accessed May 2016).
Simplex or isolated cases are defined as those non consanguineous affected individuals with no affected 
first-degree relatives (parents, siblings, and children) and no reports of more distant affected family members. 
Although clinical examination of extended family members can often be revealing, the genetic approach of spo-
radic cases is complex. Traditionally, sRP cases have been considered recessive cases, with unaffected carrier 
parents. This is certainly true in many cases, but there are other possibilities. Perhaps, one parent is a carrier but 
the other mutation is de novo. Alternatively, it is estimated that de novo mutations in dominant inheritance genes 
are responsible for at least 1–2% of isolated cases4 and at least 15% of affected males of sRP harboured mutations 
in the xlRP genes RPGR and RP28. Moreover, incomplete penetrance, or nonpenetrance, in prior generations can 
also confuse the picture of sRP9. All these concerns can be confusing for the patient, who may require a more 
detailed explanation and genetic counselling, and in some cases, it may be even necessary to redefine the family 
disease.
In this regard, molecular genetic testing is crucial, but also challenging, for sRP patients, who can carry causa-
tive mutations in any of the 81 known RP genes. The next-generation sequencing (NGS) technologies introduced 
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in the last few years have shown to be very helpful in the molecular diagnosis of IRD families10. Moreover, the 
development of population specific targeted gene panels allows a more efficient interpretation of sequence var-
iations and overcomes limitations associated with the large amount of data generated by higher performance 
platforms11,12.
Herein, we report an in-house targeted gene panel approach to uncover the genetic cause of 106 sRP Spanish 
families. The diagnostic rate was 62.26% (66 of 106), demonstrating the high efficiency of this genomic approach. 
Our data revealed that the solved sRP cohort is composed of 62.1% of arRP cases, 24.2% of adRP and 13.6% of 
xlRP, which implies consequences for counselling of patients and families. These findings represent a significant 
advance in efforts to unravel the genetic basis of sRP.
Results
Clinical features. All index patients included in this study received an initial clinical diagnosis of simplex 
RP. However, due to the high clinical heterogeneity of this disease, diverse clinical manifestations were found 
(Supplementary Table S1 and data not shown). The majority of cases (~70%) showed typical RP with initial night 
blindness and at least two of the classic fundus findings (bone-spicule pigmentation, narrowed vessels and pale 
optic disc). The remaining cases presented different degrees of macular involvement and other initial symptoms 
(reduced visual field or decreased visual acuity). The age of onset and the progression of the disease were variable 
among families and additional findings such as photophobia, myopia, cataracts, dischromatopsia and nystagmus 
were found in ~45% of cases.
Reliability of NGS data. The reliability of NGS data depend on three criteria: depth of coverage, heteroge-
neity and accuracy of sequencing. On average, sequencing and mapping resulted in a mean coverage of 742.1x 
and a percentage of reads mapping on target of 96.7%. Within the targeted region, ~95% of the bases were covered 
> 100x and ~65% > 500x, which indicated that sufficient coverage was achieved for sensitive detection of variants. 
Application of variant calling allowed obtaining a mean of 847 raw variants per sample, which were filtered and 
annotated to identify causative mutations. Variants present in the two positive-control samples were successfully 
detected after the bioinformatics analysis, demonstrating the diagnostic accuracy of this approach.
Identification and assessment of candidate variants. Application of the data analysis pipeline allowed 
the identification of 96 potential causative mutations in 66 out of the 106 families (62.26%) (Table 1). However, 
given the difficulty of obtaining samples from additional relatives in sporadic cases in which there is only one 
affected member, we could perform segregation analysis in only 21 out of 66 families. Most mutations in the 
remaining cases were considered as the likely disease cause since they were consistent with previously reported 
genotype-phenotype correlations and met the established pathogenicity criteria (see Material and Methods sec-
tion). Seventeen of these families need additional studies to achieve a full diagnosis since the nature of the muta-
tion (synonymous and possible dominant de novo variants) and the absence of available family members did not 
allow us to complete the required studies to obtain a reliable estimation of their pathogenicity. Still, a minimum 
diagnostic rate of 46.22% was achieved by the application of this IRD panel. Remarkably, the majority of the 
in silico splicing prediction tools showed that all these synonymous and splicing variants were probably damaging. 
Of note, patients will not be informed until segregation studies confirm the pathogenicity of the detected variants.
Detected candidate variants included 3 CNVs, 47 missense, 6 synonymous, 13 nonsense, 15 frameshift, 3 
nonframeshift, 1 intronic and 8 splicing mutations (Fig. 1A). Thirty three of these variants were novel and absent 
in public databases (Table 1). Specifically, we found homozygous or compound heterozygous mutations in auto-
somal recessive IRD disease genes in 41 cases, heterozygous mutations in autosomal dominant IRD-associated 
genes in 16 cases and mutations in X-linked disease genes in 9 cases (Fig. 1B). The most frequent mutated gene for 
autosomal recessive cases of this study was USH2A, for autosomal dominant cases was PRPF31 and for X-linked 
cases was RPGR (Fig. 1C). In addition, although most causative mutations were specific to one family, we found 
recurrence for 6 of them, including: p.C759F of USH2A (5 cases), p.R303H of USH2A (3 cases), p.R257* of 
CERKL (3 cases), p.E767fs of USH2A (2 cases), p.I205fs of CRB1 (2 cases) and p.S542* of RP1 (2 cases). Finally, 
the proportion of type of mutations for each of the mutated genes is shown in Fig. 1D.
Clinical refinements and genotype-phenotype correlations. After clinical reassessment, almost 
one-third of the cases showed clinical characteristics inconsistent with RP, which led to clinical diagnosis refine-
ments taking into account the obtained genotypes. Thus, the diagnosis was modified from RP to Leber Congenital 
Amaurosis (LCA) in 7 cases, to choroideremia (CHM) in 3 cases, to cone-rod dystrophy (CRD) in 5 cases, to 
Stargardt disease (STGD) in 2 cases, to Usher syndrome (USH) in 2 cases and to macular dystrophy in 1 case 
(Supplementary Table S1). These results revealed that the considerable variation in clinical expression and phe-
notypic overlapping of single IRD entities hamper an accurate clinical diagnosis (Fig. 2A).
Although IRD-associated genes have been extensively studied so far, genotype-phenotype correlations are 
incompletely understood since many different genes may result in a similar disease phenotype and multiple clin-
ical features may be caused by mutations in the same gene. In this regard, we found that mutations in CRB1, 
CEP290, PROM1, CERKL, USH2A, GUCY2D and ABCA4 genes were involved in several disease phenotypes, and 
genes RPGR, PDE6B and RP1 were acting under different modes of inheritance (Fig. 2A and B). Furthermore, 
our data have shown a relationship between the age of onset of symptoms and the disease-causing gene (Fig. 2C). 
Likewise, the proportion of early, juvenile and late IRD for each inheritance mode is shown in Fig. 2D.
Finally, this study has revealed interfamilial phenotypic variability involving the known pathogenic muta-
tions p.R1129L of ABCA4 and p.R257* of CERKL. The mutation p.R1129L of ABCA4 was previously reported 
as causative of Stargardt disease but we found this mutation in homozygosis in the affected member of family 
#84, diagnosed of RP. Considering the presence of phenotype modifiers, we reanalyzed the NGS data and the 
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ID N° Gene
Allele 1 Allele 2 Family Segr. 
(Size)cDNA Protein Ref. cDNA Protein Ref.
Mutations in autosomal recessive genes
4 ABCA4 c.52C> T p.R18W 34 c.1222C> T p.R408* 35 Yes (3)
84 ABCA4 c.3386G> T p.R1129L 30 c.3386G> T p.R1129L 30 NA
51 BBS2 c.1176_1184del p.N393_T395del This study c.1175G> A p.G392E This study NA
100 C2orf71 c.3099_3100insCAGG p.V1034fs ExAC c.3099T> C p.P1033P ExAC NA(†)
27 CEP290 c.4393C> T p.R1465* 36 c.4705-1G> T splice site 4 Yes (6)
61 CEP290 c.6604delA p.I2202fs 37 c.6604delA p.I2202fs 37 Yes (3)
93 CEP290 c.7328_7332delAGAAG p.E2443fs 38 c.2991+ 1655A> G deep intronic 39 NA(†)
119 CEP290 c.4028delA p.K1343fs 37 c.2929A> G p.R977G ExAC NA
2 CERKL c.769C> T p.R257* 40 c.769C> T p.R257* 40 Yes (4)
53 CERKL c.769C> T p.R257* 40 c.769C> T p.R257* 40 NA
55 CERKL c.769C> T p.R257* 40 c.769C> T p.R257* 40 NA
14 CRB1 c.2227delG p.V743fs 41 c.3299T> C p.I1100T 42 Yes (3)
24 CRB1 c.613_619del p.I205fs 43 c.2843G> A p.C948Y 44 Yes (3)
37 CRB1 c.613_619del p.I205fs 45 c.498_506del p.I167_G169del 45 NA
44 CRB1 c.2290C> T p.R764C 44 c.2290C> T p.R764C 44 NA
45 CRB1 c.848+ 1G> A splice site This study c.848+ 1G> A splice site This study NA
85 CRB1 c.4006T> A p.L1336M This study c.4082T> A p.L1361Q This study NA
56 EYS c.35T> C p.M12T 46 c.35T> C p.M12T 46 NA
115 GPR98 c.13757A> T p.E4586V CSVS c.7176C> T p.S2392S 47 NA(†)
12 GUCY2D c.3119G> A p.R1040Q This study c.3119G> A p.R1040Q This study Yes (4)
60 MYO7A c.1993A> G p.I665V This study c.4008delG p.E1337fs This study Yes (5)
23 PDE6B c.385G> A p.E129K This study c.385G> A p.E129K This study Yes (4)
81 PDE6B c.984delG p.V329fs This study c.984delG p.V329fs This study NA
122 PROM1 c.1984-1G> T Splice site 48 c.1984-1G> T splice site 48 Yes (4)
95 RDH12 c.278T> C p.L93P 49 c.464C> T p.T155I 50 NA
10 RP1 c.1625C> G p.S542* 54 c.5881C> T p.Q1961* ExAC Yes (3)
49 RP1 c.1625C> G p.S542* 54 c.C1625G p.S542* 51 NA
17 USH2A c.1391G> A p.R464H This study c.13822C> T p.R4608* 52 Yes (5)
36 USH2A c.2276G> T p.C759F 53 c.908G> A p.R303H 54 Yes (3)
46 USH2A c.2276G> T p.C759F 53 c.12294+ 1G> A splice site This study NA
66 USH2A c.2299delG p.E767fs 55 c.908G> A p.R303H 54 NA
69 USH2A c.2299delG p.E767fs 55 c.12371C> G p.P4124R This study NA
71 USH2A c.7525C> T p.R2509W 56 c.13576C> T p.R4526* 57 NA
73 USH2A c.2276G> T p.C759F 53 c.920_923dup p.H308fs 58 NA
74 USH2A c.2276G> T p.C759F 53 c.4645C> T p.R1549* 59 NA
79 USH2A c.12575G> A p.R4192H 60 c.1841-2A> G — 42 NA
87 USH2A c.2276G> T p.C759F 53 c.13808A> C p.H4603P This study Yes (5)
103 USH2A c.11156G> A p.R3719H 61 c.12569T> A p.V4190E This study NA
108 USH2A c.908G> A p.R303H 54 c.10403C> T p.P3468L This study NA
114 USH2A c.10712C> T p.T3571M 62 c.10712C> T p.T3571M 62 NA
101 ZNF408 c.1342C> T p.R448C ExAC CSVS c.1572C> A p.Y524* This study NA
Mutations in autosomal dominant genes
7 C+ PRPF8 c.6994dupG p.D2332fs 11 Yes(#)
8 C+ RHO c.(937–2_944)del Splice site 12 Yes
15 RHO c.403C> T p.R135W 63 Yes(#) (6)
68 RHO c.316G> A p.G106R 64 NA
33 CRX Deletion ex3–4: c.(100+ 1_101–1)_(*1097_?)del Unable to predict 11 NA
48 FSCN2 c.908G> A p.C303Y ExAC NA(†)
39 GUCY2D c.160T> A p.F54I This study NA(†)
83 GUCY2D c.1912C> A p.L638M This study NA(†)
35 PDE6B c.754G> A p.D252N This study NA(†)
112 PDE6B c.263A> G p.Q88R This study NA(†)
102 PRPF31 c.238+ 1G> A Splice site This study NA(†)
104 PRPF8 c.6926A> G p.H2309R 65 NA(†)
Continued
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ID N° Gene
Allele 1 Allele 2 Family Segr. 
(Size)cDNA Protein Ref. cDNA Protein Ref.
107 RP1 c.4780T> C p.Y1594H This study NA(†)
50 TOPORS c.2524dupA p.T842fs This study NA(†)
22 PROM1 c.1551A> G p.E517E This study Yes(†) (4)
91 PROM1 c.1584G> A p.L528L This study NA(†)
76 PRPF31 c.789G> A p.S263S CSVS NA(†)
97 PRPF31 c.417C> A p.V139V This study NA(†)
Mutations in X-Linked genes
 29 RPGR c.739C> T p.Q247* This study Yes (4)
 42 RPGR c.888_889delAA p.I297fs 66 NA
 59 RPGR c.2257_2260del p.G753fs 67 Yes (4)
 11 CHM
Deletion ex3–9: c.(116+ 
1_117–1)_(1244+ 1_1245–1)
del
Unable to predict This study Yes (4)
 94 CHM c.315-2A> G Splice site This study NA
 65 (F) OFD1 RS1 Large deletion Chr X (p22.2–p22.13) Unable to predict This study NA
 116(F) CHM c.238C> T p.L80F 68 NA
 70(F) RP2/RPGR RP2:c.995C> T p.T332M ExAC RPGR: c.347_349delAAG p.E116del This study NA(†)
 78(F) RPGR c.619+ 1 G> T Splice site This study Yes (2)
Table 1.  Causal and likely causal mutations identified in the 68 characterized RP cases, including 2 
positive controls and 66 sRP individuals. (C+ ): positive controls. CSVS: Variant present in the Ciberer 
Spanish Variant Server. ExAC: Variant present in the Exome Aggregation Consortium; EVS: Variant present in 
the Exome Variant Server; (F): Female (X-linked dominant); Size: Number of members of the family included 
the index patient. NA: No additional family members available; (#): de novo mutation; (†): Likely solved 
families, further studies needed.
Figure 1. Prevalence analyses of solved cases. (A) Proportion of each type of mutation. (B) Principal detected 
modes of inheritance. (C) Recurrence of all mutated retinal genes. (D) Distribution of different types of 
mutations for each of the identified mutated gene.
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recessive pathogenic RP1 mutation p.R396* was found in heterozygosis. Secondly, we identified the homozygous 
disease-causing CERKL mutation p.R257* in three unrelated cases (#2, #53 and #55). This mutation is commonly 
associated with typical RP but the affected member of family #53 showed substantial macular involvement absent 
in the other two cases. No further variants were found by data reanalysis.
Unsolved cases and variants of uncertain significance. We did not detect sequence alterations that 
completely explain the disease phenotype in 40 index patients (37.7%). In six cases, we found missense variants 
predicted as pathogenic but their high frequency in control populations led us to discard them as causative muta-
tions. In addition, we identified potential pathogenic variants in 19 cases, including two heterozygous CNVs 
in EYS, five heterozygous pathogenic mutations in ABCA4, two heterozygous missense variants in GPR98 and 
CEP290, and eight heterozygous mutations in BBS12, CNGB3, NR2E3, PCDH15, PROM1, RP1, RPGRIP1 and 
USH2A, respectively (Supplementary Table S2). However, these mutations did not explain the disease by them-
selves and no second allele was found. In two other cases we found the combination of heterozygous exonic vari-
ants and heterozygous novel intronic variants that could be causative in compound heterozygosity. Nevertheless, 
these intronic mutations were categorized as unclear since further studies would be needed to evaluate their 
pathogenic role. Moreover, we detected two potential pathogenic mutations in EYS that did not segregate with the 
disease in one family. Finally, no candidate variants were found in the remaining 12 cases.
Discussion
In this study, we performed targeted sequencing of 68 retinal genes to assist in the molecular diagnosis of 106 
sRP Spanish cases, which resulted in a pathogenic mutation-detection rate of 62.26%. This yield is comparable to 
other studies involving capture panels covering a higher number of IRD genes13, which further demonstrate that 
increasing the number of genes does not necessarily improve the diagnostic rate for a particular population, hence 
a population-specific gene panel is the most cost-efficient option11. Unsolved cases will be subjected to whole 
exome sequencing (WES) and/or whole genome sequencing (WGS) to investigate their underlying genetic defect 
that may be in one of the retinal genes not included in the panel design, in a deep intronic region (supported by 
Figure 2. Genotype-phenotype correlations. (A) Overlapping phenotypes among different forms of non 
syndromic IRD: RP (Retinitis Pigmentosa), CHM (Choroideremia), CD/CRD (Cone dystrophy/Cone-
rod dystrophy), STGD (Stargardt disease) and LCA (Leber congenital amaurosis). Gene positions show 
the associated phenotype/s and the first reported symptom of cases in which they are involved (NB: Night 
blindness; RVF: Reduced visual field; DVA: Decreased visual acuity). Asterisks indicate genes represented more 
than once in the figure due to the high heterogeneity. (B) Distribution of types of mutations behind the different 
phenotypes caused by the same gene. (C) Mean age of onset of each of the identified genes. Vertical lines show 
the age of onset of cases not included in the average to be considerably different from the rest. Of note, the gene 
RHO was identified in only two cases with very different clinical features hence the calculated average may not 
be representative. Moreover, this representation do not include clinical and genetic data of family #65 since the 
large deletion affects several genes and it is not possible to determine the involvement of each of them. Light 
blue marks early-onset cases while a juvenile onset is stated with medium blue and a late-onset with dark blue. 
(D) Distribution of early-, juvenile- and late-onset IRD for the different modes of inheritance.
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the high proportion of cases with only one pathogenic allele that does not explain the disease itself), in a new 
gene that has never been implicated in IRD or even follow other types of non-Mendelian inheritance. Therefore, 
targeted sequencing of selected IRD genes should be the primary choice in a NGS-based diagnostic routine for 
IRD and represents a powerful resource for selecting cases likely to carry mutations in new candidate genes14.
Almost 50% of RP patients are simplex cases with no family history of disease or consanguinity which makes 
it difficult to determine the mode of inheritance15. These cases may be caused by autosomal recessive, autosomal 
dominant (de novo and/or with incomplete penetrance) or X-linked gene mutations. Here, we found mutations 
following an autosomal recessive mode of inheritance in 62% of solved cases, which is in line with the traditional 
idea that most simplex cases are recessive with unaffected carrier relatives. However, mutations in the remain-
ing 38% are consistent with an autosomal dominant (24%) or X-linked (14%) inheritance, which is higher than 
reported in previous studies8,16. Further analysis would be needed to confirm the pathogenicity of these candidate 
variants and to discern which of them are de novo mutations and which are inherited cases with incomplete pen-
etrance in prior generations or with a large pedigree of female-to-female transmission, as applicable. Of note, the 
known molecular mechanisms for some genes may provide guidance on the most likely option, as occurs in cases 
with mutations in the PRPF31 gene, one of the most prevalent genes in this and other studies17, commonly show-
ing incomplete penetrance18. These results emphasize the role of genetic testing in genetic counseling and clinical 
management, and highlight the need to give greater consideration to minority patterns of inheritance, which in 
turn have a high family impact. In addition, the identification of the underlying genetic defect may be decisive 
to future applications of gene-based therapies19 and genotype-phenotype correlations will be better defined as 
genetic testing become widespread.
The relative high frequency of RP has made it the most widely studied IRD, which has led to traditionally 
classify as RP all cases capable of being although clinical features were also consistent with other conditions. This, 
together with overlapping phenotypes, explains somehow the high proportion of clinical refinements obtained in 
this study (30.3%), although we expect it to lessen over time due to the progress made in ophthalmic techniques 
and in the knowledge of different IRD. Nevertheless, the extreme clinical and genetic heterogeneity of IRD will 
remain a problem to establish accurate genotype-phenotype correlations. Despite this, the genetic data obtained 
here allowed us to correlate the age of onset of symptoms with the causative gene and the mode of inheritance. 
As a result, while early-onset forms of the disease were the most common in all inheritance modes, only auto-
somal dominant cases showed a large group of late-onset forms. These results were in accordance with previous 
published studies in which autosomal dominant cases were considered milder forms of RP with later onset and 
tendency to retain good visual acuity20.
Remarkably, these results also allowed us to propose that the development of the disease depends on the type 
of causative mutations. We have observed that although most of pathogenic variants were missense, they were not 
randomly distributed among different genes and modes of inheritance. For example, PRPF31 and RPGR did not 
show missense mutations and presented a clear preference for splicing and stop-gained mutations, respectively, 
which is in accordance with previous studies17,21. Moreover, genes involved in more than one mode of inheritance 
also showed different proportion for each type of mutations. For instance, synonymous and missense variants 
were predominantly associated with autosomal dominant forms implicating PROM1 and RP1 genes, whereas 
splicing and nonsense mutations were primarily related to autosomal recessive cases. Although the mechanisms 
underlying the effect of each mutation on the aetiology of IRD are still unknown, we suggest that variants result-
ing in prematurely truncated proteins, or transcripts degraded by the NMD (Nonsense-mediated mRNA decay) 
pathway, were associated with a loss of protein function leading to recessive forms of IRD, while a priori less 
damaging mutations may result in a gain of function of the protein with further deleterious effects22.
Furthermore, we found that USH2A was the most frequently mutated gene, which is in line with previous 
reports23. This gene is commonly associated with Usher syndrome and non-syndromic RP but, after clinical reas-
sessment, two solved cases harbouring USH2A mutations presented clinical characteristics resembling CRD. 
This association has been previously reported24, expanding the spectrum of phenotypes associated with USH2A 
mutations ranging from syndromic and nonsyndromic RP to isolated CRD. Likewise, four additional genes, 
CEP290, PDE6B, PROM1, and GUCY2D, were suggested as causative in cases with clinical features not previously 
associated with them (#22, #35, #39, #83, #112 and #119) but further analysis will be required to confirm the seg-
regation of the variants with the phenotype, the initial clinical diagnosis and the novel genotype-phenotype cor-
relations. Moreover, regarding genes with both dominant and recessive alleles, the absence of family segregation 
does not allow us to rule out the possibility that the disease in a priori dominant cases is inherited as a recessive 
trait with a second mutation in an unanalyzed region. On the other hand, our results support previously reported 
genotype-phenotype correlations such as the involvement of the gene ZNF408 in RP25.
Although most causative mutations associated with IRD are extremely rare, certain variants are remarkably 
recurrent. An example is the p.C759F mutation of USH2A, found in a total of 5 cases in this study. While this 
mildly deleterious variant is widely associated with non-syndromic RP in heterozygosis12, another USH2A fre-
quent change, the c.2299delG mutation, causes mainly Usher syndrome26. However, the two cases harbouring 
this heterozygous frameshift mutation showed typical RP without hearing loss (#66 and #69), which may indi-
cates low pathogenicity of the second heterozygous missense variant (p.P412R and p.R303H, respectively). In 
this regard, genetic findings of this study allowed us to consolidate the association between a specific mutation 
and a given phenotype. On one hand, the only two cases with LCA caused by CRB1 (#24 and #37) shared the 
same heterozygous mutation (p.I205fs) which indicates the correlation of this variant with this severe phenotype. 
This is noteworthy because CRB1 mutations lead to a highly variable spectrum of clinical phenotypes but no 
genotype-phenotype correlations has been established except that CRB1 null mutations may be over-represented 
in LCA cases27. Similarly, family #68 was found to carry the heterozygous c.316G > A RHO mutation which was 
identified as causal of sector RP as previously described28.
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Importantly, these results allowed us to uncover interfamilial phenotypic variability under the same patho-
genic allele in two cases. First, one of the most common CERKL mutations (p.R257*) was detected in three unre-
lated families but only one (#53) showed macular involvement. Although CERKL mutations are widely associated 
with both typical RP and CRD29, further studies will be needed to elucidate the cause of this interfamilial varia-
bility. We hypothesize that additional genetic and environmental modifiers may be modulating the development 
of the disease. Secondly, a previously STGD-associated ABCA4 mutation (p.R1129L)30 was found in a family 
clinically classified as RP (#84). No clinical features of STGD were found after clinical reassessment but data rea-
nalysis showed a nonsense RP1 mutation in heterozygosis (p.R396*) that could be acting as a phenotype modifier, 
indicating a potential epistatic effect of ABCA4 and RP1 mutations.
In summary, properly perform genotype-phenotype correlations is repeatedly hampered due to the extreme 
heterogeneity of IRD but a suitable approach may greatly facilitate this arduous task. This is even more important 
when it comes to simplex cases in which the mode of inheritance is not inferred by the pedigree and the genetic 
diagnosis is critical to estimate the family impact of mutations and to take appropriate actions. This study has 
further demonstrated that combining both a population specific panel design and the prioritization of variants 
using local genetic data, allow obtaining higher diagnostic accuracy. Moreover, our results reinforced the idea that 
the most common mode of inheritance of simplex RP cases is autosomal recessive while at the same time it has 
revealed that X-linked and autosomal dominant forms are probably being underestimated with all implications 
this entails.
Methods
Subjects and Clinical Data. Our current cohort of study involved 108 unrelated Spanish families, compris-
ing 106 sRP cases with no known mutations and two genetically solved adRP cases included as positive controls 
of mutations10,11. Additionally, our study cohort included 118 samples from healthy relatives belonging to 42 
families, in case segregation studies of candidate variants were needed.
The study was carried out in accordance with the tenets of the Declaration of Helsinki and all experimen-
tal protocols were approved by the Institutional Review Boards of the University Hospital Virgen del Rocio 
(Spain). Prior to analysis, written informed consent was obtained from all participants or their respective legal 
representative.
Clinical diagnosis of RP was based on a full ophthalmic examination, fundus photography, perimetry, colour 
vision, full field and multifocal electroretinography (ERG). RP was defined as bilateral visual loss, initial hemer-
alopy, restriction of visual field, gradual increased bone spicule pigmentation, attenuation of retinal vessels, waxy 
disc pallor and reduced or extinguished ERG. Genomic DNA of all subjects was isolated from peripheral blood 
using standard protocols and its integrity was verified using both the fluorometric dsDNA quantification and 
agarose gel electrophoresis.
Additionally, we have used the Spanish population variant server web page (CIBERER Spanish Variant Server, 
CSVS, publicly available http://csvs.babelomics.org/), that contains population frequency information from the 
whole exome sequencing of 267 unrelated individuals, representative of the healthy Spanish population (Medical 
Genome Project, MGP)31.
Capture panel design. A custom IRD panel was developed using SeqCap EZ Choice System (Roche, 
NimbleGen, Madison, WI) to cover all exons plus 25 bp of intronic flanking regions of 68 genes, among them 
65 known to be associated with monogenic retinal disorders in Spanish population and 3 candidate genes. 
Additionally, three deep intronic regions of USH2A, CEP290 and OFD1 genes, containing known pathogenic 
mutations, were also covered. The genes were selected and compiled from literature or databases as previously 
described11. The probes covered a total of 1,245 regions and the entire custom design spanned 369,318 bp (panel 
details available upon request).
DNA library preparation and targeted sequencing. Genomic DNA (gDNA; 1 μ g) was sheared using 
Covaris S220 sonicator to achieve target peak of 180 to 220 bp (SonoLab 7.2 settings: Peak Incident Power, 175 W; 
Duty Factor, 10%; cycles per burst, 200; Temperature, 7 °C Duration, 160 seconds) (Covaris, Woburn, MA). 
Library preparation was performed according to the double capture manufacturer’s protocol (NimbleGen SeqCap 
EZ Library Double Capture (version 4.2)). The library pooling guideline was followed to capture 7 samples at once 
(“Multiplex DNA Sample Library Pool”). After amplification, the index-tagged libraries were then quantified 
using the Agilent 2100 Bioanalyzer (Agilent Technologies), qPCR and fluorimetric measurements. The library 
peak size was in the range of 150 to 500 bp. Finally, multiplexed libraries were pooled (2 × 7; 14 samples per run) 
and diluted to 2 nM for sequencing on Illumina’s MiSeq instrument using a v2 (300 cycles) reagent kit.
Sequence data analysis. Results were analyzed using our validated data analysis pipeline32 with 
some modifications. Sequence reads were aligned to the reference human genome sequence (hg19) by using 
Burrows-Wheeler Aligner (BWA, version 0.7.12). The coverage and the percentage of reads on target were ana-
lyzed using the BEDtools package. SNVs and indels were called using GATK software (version 1.4) and filtered 
to eliminate low quality SNVs (coverage < 20x and strand bias). Remaining variants were functionally annotated 
by ANNOVAR33 and those with a MAF higher than 0.015 in at least one of the searchable databases (dbSNP, 1000 
Genomes, EVS, ExAC) were excluded. Additionally, the presence of all candidate variants was checked in the 
MGP 267 unrelated individuals, representative of the healthy Spanish population31. On the other hand, as pre-
viously described11, we used the Surecall software (Agilent) with the “pair analysis” option for the identification 
of potential copy number variations (CNVs) and to discard hemizygosis in patients with mutations detected in 
homozygosis in which family segregation could not be performed.
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Pathogenicity assessment. Sequence variants considered to be likely disease causing mutations in this 
study were: (i) those previously documented to be pathogenic in the literature, (ii) large deletions and duplica-
tions (CNVs), (iii) novel nonsynonymous variants, (iv) nonsynonymous variants that are not novel but its allele 
frequency retrieved in any of the public exome databases (such as 1000 genomes project, ExAC, EVS and CSVS) 
is < 0.015 and there are no homozygous/hemizygous carriers, (v) synonymous variants predicted to affect splicing 
process.
Once the list of candidate variants was prioritized, we evaluated the association of these mutations with the 
particular phenotype of each individual considering the genotype-phenotype correlations described in the bibli-
ography, entries listed in the OMIM database and expert opinion. Clinical features of patients with mutations in 
genes not classically associated with RP were reviewed in order to reassess initial diagnosis.
The pathogenicity of novel non-synonyms SNVs was predicted by PolyPhen-2 (http://genetics.bwh.harvard.
edu/pph2/) and SIFT (http://sift.bii.a-star.edu.sg) algorithms. Additionally, to estimate the effect of synonyms or 
intronic mutations on the splicing process we used NNSPLICE (http://www.fruitfly.org/seq_tools/splice.html), 
Mutation Taster (http://www.mutationtaster.org/), Human Splicing Finder (HSF; http://www.umd.be/HSF) or 
NetGene2 (http://www.cbs.dtu.dk/services/NetGene2/). The nomenclature of variants was adjusted to the Human 
Genome Variation Society (http://www.hgvs.org) guidelines using Mutalyzer (http://www.LOVD.nl/mutalyzer).
In cases where a single heterozygous pathogenic mutation was found in a gene linked to an autosomal reces-
sive trait, we evaluated the implication of a complementary rare intronic or synonymous variant in the same gene 
explaining the phenotype. In cases where no causal mutation was found, we manually searched for regions with 
unusually coverage 0x indicating a possible homozygous or hemizygous deletion.
Validation of candidate variants and Segregation analysis. Sanger sequencing was performed to 
validate all the pathogenic and likely pathogenic sequence variants. To further determine the impact of candidate 
variants, we conducted the segregation analysis in available family members. Specifically in 21 families (Table 1), 
samples from 62 additional members were used to verify segregation of the sequence alteration with the pheno-
type by conventional Sanger sequencing according to the manufacturer’s protocols (3730 DNA Analyzer, Applied 
Biosystems, USA) (Primer sequences and reaction conditions are available upon request).
Furthermore, exon deletions and duplications were validated by multiplex ligation dependent probe ampli-
fication (MLPA), specifically SALSA MLPA probes P322 and P361 were used following manufacturer’s recom-
mendations (MRC Holland, Amsterdam, The Netherlands). Additionally, the validation of the large deletion 
comprising OFD1 and RS1 (Xp22.2–22.13), in which commercial MLPA was not available, was performed using a 
qPCR assay (primers available upon request). The qPCR was performed on an ABI Prism 7500HT Fast Real-Time 
PCR System with SYBR Green (Bio-Rad, USA).
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